XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.
G
G

Gilead

Yangiliklar

Reuters - 10 soat oldin

Gilead Sciences Inc reports results for the quarter ended in June - Earnings Summary

Gilead Sciences Inc reports results for the quarter ended in June - Earnings Summary Gilead Sciences Inc GILD.OQ reported quarterly adjusted earnings of $2.01​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.66. The mean expectation of twenty three analysts for the quarter was for earnings of $1.60 per share.
G
Reuters - 10 soat oldin

Gilead quarterly profit beats Street estimates, revenue up 5%

UPDATE 1-Gilead quarterly profit beats Street estimates, revenue up 5% Adds analyst comment, share price, paragraphs 4-6 By Deena Beasley Aug 8 (Reuters) - Gilead Sciences GILD.O on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings.
G
Reuters - 11 soat oldin

Gilead quarterly profit beats Street estimates, revenue up 5%

Gilead quarterly profit beats Street estimates, revenue up 5% By Deena Beasley Aug 8 (Reuters) - Gilead Sciences GILD.O on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings. The Foster City, California-based company posted a quarterly profit of $2.01 per share excluding items, on revenue of $7 billion, up from $1.34 a share and revenue of $6.6 bi
G
Reuters - 11 soat oldin

Gilead Q2 EPS USD 1.29

BRIEF-Gilead Q2 EPS USD 1.29 Aug 08 (Reuters) - Gilead Q2 product sales USD 6,912 million. Q2 operating income USD 2,644 million Q2 pretax profit USD 2,053 million vs. IBES estimate USD 2,593 million Q2 net income USD 1,614 million Q2 basic EPS USD 1.29
G
Reuters - 19 soat oldin

Merck stops testing combo drug for lung cancer

UPDATE 1-Merck stops testing combo drug for lung cancer Adds details in paragraphs 2 and 6, background throughout Aug 8 (Reuters) - Merck MRK.N said on Thursday it had discontinued a trial testing a combination immunotherapy treatment in patients with a type of lung cancer after an interim analysis showed the drug was unlikely to succeed. The patients tested with a combination of its experimental drug, vibostolimab, with Keytruda experienced a higher rate of immune-related side effects, Merck sa
G
Reuters - 21 soat oldin

Markets stay bumpy awaiting jobs reality check

MORNING BID AMERICAS-Markets stay bumpy awaiting jobs reality check A look at the day ahead in U.S. and global markets from Mike Dolan Seeking some calm, markets remain edgy following the volatility jolt of the past week and traders now seek some re-assurance the real economy has not shifted underneath them. Volatility spikes like the one seen on Monday rarely disappear instantly and, with the VIX 'fear gauge' .VIX still above historical averages of about 20 , some turbulence remains.
A
E
G
N
N
U
T
J
U
U
U
F
M
Reuters - 2 kun oldin

What to Watch in the Day Ahead - Thursday, August 8

What to Watch in the Day Ahead - Thursday, August 8 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT The Labor Department's weekly jobless claims report will be widely watched by investors after weaker-than-expected July jobs data last week fueled to a stock market rout.
G
N
Reuters - 2 kun oldin

Gilead Sciences Inc <GILD.OQ> expected to post earnings of $1.60 a share - Earnings Preview

Gilead Sciences Inc expected to post earnings of $1.60 a share - Earnings Preview Gilead Sciences Inc GILD.OQ GILD.O is expected to show a rise in quarterly revenue when it reports results on August 8 for the period ending June 30 2024 The Foster City California-based company is expected to report a 1.8% increase in revenue to $6.719 billion from $6.6 billion a year ago, according to the mean estimate from 21 analysts, based on LSEG data.
G
Reuters - 2 hafta oldin

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Atlassian Corp TEAM.OQ +7.4% Old Dominion Freight Line Inc ODFL.OQ +5.8% MongoDB Inc MDB.OQ +5.7% O'Reilly Automotive Inc ORLY.OQ +4.3% Gilead Sciences Inc GILD.OQ +4.0% Bottom Performers Percent Change Lululemon Athletica Inc LULU.OQ -8.2% Warner Bros Discovery Inc WBD.OQ -5.4% Honeywell International Inc HON.OQ -4.9% Arm Holdings PLC ARM.OQ -4.6% Booking Holdings Inc BKNG.OQ -3.
G
L
U
A
B
O
Reuters - 2 hafta oldin

Gilead climbs on positive data from HIV drug trial

BUZZ-Gilead climbs on positive data from HIV drug trial ** Shares of drugmaker Gilead Sciences GILD.O rise ~2.6% to $73.05 ** Co says its HIV prevention drug Lenacapavir showed zero infections and 100% efficacy and superiority against a daily dose of its HIV treatment Truvada ** Says patients showed high adherence to the injectable drug during the late-stage trial ** "We see GILD's HIV business supporting most, if not all, of the company's current market cap" say analysts at J.P.
G
Reuters - 2 hafta oldin

Pharma aims to deliver personalized cancer therapies more quickly

FOCUS-Pharma aims to deliver personalized cancer therapies more quickly By Michael Erman NEW YORK, July 24 (Reuters) - Big pharmaceutical companies that make personalized blood cancer treatments are working to cut the manufacturing turnaround time by as much as half in coming years, as they try to deliver them sooner in a patient's disease course.
G
N
Reuters - 1 oy oldin

U.S. STOCKS Gold miners, Nikola, Cruise stocks

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Nikola, Cruise stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Chip stocks boosted the Nasdaq on Monday, while the S&P 500 and the Dow edged lower as investors awaited a key inflation reading, commentary from Federal Reserve Chair Jerome Powell and the start of corporate earnings season for monetary policy cues.
C
G
I
J
N
Q
T
U
U
R
S
V
F
M
Reuters - 1 oy oldin

U.S. STOCKS Ally Financial, Ideaya Biosciences, Brinker

BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Ideaya Biosciences, Brinker Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 hit record highs on Monday, while the Dow scaled a more than one-month high as investors awaited a key inflation report, Congressional testimony from Federal Reserve Chair Jerome Powell and the start of earnings season this week.
B
C
G
I
J
N
Q
T
U
U
H
S
V
F
M
Reuters - 1 oy oldin

U.S. STOCKS Boeing, Gilead Sciences, Bumble

BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Gilead Sciences, Bumble Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were on track for a listless open on Monday, in a week packed with crucial inflation readings, Congressional testimony from Federal Reserve Chair Jerome Powell and the start of the corporate earnings season.
B
G
T
U
H
S
F
Reuters - 1 oy oldin

Gilead Sciences rises as brokerage upgrades to 'outperform'

BUZZ-Gilead Sciences rises as brokerage upgrades to 'outperform' ** Gilead Sciences' GILD.O shares rise 3.1% to $68.74 premarket ** Brokerage Raymond James raises its rating on company's shares to "outperform" from "market perform" ** Outstanding data from a study of Gilead's long-acting drug lenacapavir in HIV and expected approval of liver diseas
G
Reuters - 1 oy oldin

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +6.5% NVIDIA Corp NVDA.OQ +4.6% Broadcom Inc AVGO.OQ +4.3% Micron Technology Inc MU.OQ +3.2% Arm Holdings PLC ARM.OQ +2.9% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Gilead Sciences Inc GILD.OQ -2.6% Regeneron Pharmaceuticals Inc REGN.OQ -2.0% Biogen Inc BIIB.OQ -1.8% O'Reilly Automotive Inc ORLY.OQ -1.6% The Nasdaq 100 .NDX gained
B
B
G
M
N
R
T
W
U
Reuters - 1 oy oldin

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change Paramount Global PARA.OQ +6.9% First Solar Inc FSLR.OQ +6.6% Tesla Inc TSLA.OQ +6.5% Vistra Corp VST.N +4.6% NVIDIA Corp NVDA.OQ +4.6% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Constellation Brands Inc
G
N
T
W
U
Reuters - 1 oy oldin

Cellares Kite, A Gilead Company, Will Evaluate Co's Automated Manufacturing Platform Cell Shuttle

BRIEF-Cellares Kite, A Gilead Company, Will Evaluate Co's Automated Manufacturing Platform Cell Shuttle June 27 (Reuters) - Gilead Sciences Inc GILD.O : CELLARES: KITE, A GILEAD COMPANY, WILL EVALUATE CO'S AUTOMATED MANUFACTURING PLATFORM CELL SHUTTLE Source text for Eikon: ID:nBw10TJNsa Further company coverage: GILD.O
G
Reuters - 2 oy oldin

U.S. stocks weekly: Heat advisory

RPT-BUZZ-U.S. stocks weekly: Heat advisory Repeats from Friday with no changes to text. Updates chart ** S&P 500 .SPX gains third consecutive week, advances 0.6% .N ** Indeed, benchmark index heating up just as summer solstice hits ** And Nasdaq .IXIC ekes out third-straight weekly gain, though it may be flying on fumes ** Most sectors toasty; Consumer Discretionary and Energy bake most, while Tech and bond-proxies cool off; this, as Growth .IGX was on pace for its best month vs Value .IVX in 24
A
A
G
M
N
U
U
Reuters - 2 oy oldin

U.S. CarMax, Eli Lilly, MicroStrategy

U.S. RESEARCH ROUNDUP-CarMax, Eli Lilly, MicroStrategy June 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CarMax, Eli Lilly and MicroStrategy, on Monday. HIGHLIGHTS * CarMax Inc KMX.N : RBC raises target price to $75 from $73 * Eli Lilly LLY.N : Jefferies raises target price to $1,015 from $994 * MicroStrategy Inc MSTR.O : Canaccord Genuity cuts target price to $1,826 from $2,047 * Sharecare Inc SHCR.O : Canacco
A
A
B
D
G
M
N
V
E
F
T
E
P
R
T
C
C
I

Shartlar

Ommabop aktivlar

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.